MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Drug-induced parkinsonism(DIP)"

  • MDS Virtual Congress 2020

    Neuroprotective effects of allicin microemulsion against intrastriatal rotenone and manganese induced Parkinsonism in rats

    S. Singh (Moga, India)

    Objective: Allicin is flavonoid that possess neuroprotective potential but main impediment is its low bioavailability which was improved with microemulsion. The present study was framed…
  • MDS Virtual Congress 2020

    Predictors of Underlying Neurodegeneration in Drug-Induced Parkinsonism

    W. Aamodt, J. Dubroff, G. Cheng, B. Taylor, S. Wood, J. Duda, J. Morley (Philadelphia, PA, USA)

    Objective: To examine a cohort of Veterans with drug-induced parkinsonism (DIP) using [123I]Ioflupane single photon emission computed tomography (DAT-SPECT) to identify those with nigrostriatal degeneration…
  • MDS Virtual Congress 2020

    Inertial-sensor based full-body kinematics reveals an unstable gait with increased variability in patients with evidence of dopaminergic denervation with 123I-FP-CIT SPECT

    M. Mendonça, J. Silva, F. Oliveira, A. Oliveira-Maia, J. Ferreira, D. Costa, R. Costa, R. Matias (Lisboa, Portugal)

    Objective: Distinguish patients with and without dopaminergic denervation (as assessed by 123I-FP-CIT-SPECT – DaTscan) with Inertial-sensor full body kinematics (FBK) assessment. Background: The differential diagnosis…
  • MDS Virtual Congress 2020

    Comparing the effects of rosemary and selegiline on behavioral symptoms of Parkinson’s animal model in mice

    M. Modaresi (Isfahan, Islamic Republic of Iran)

    Objective: Parkinson is from common disorders of central nervous system and the second disease in neurodegenerative diseases which occurs in 1% of people over the…
  • MDS Virtual Congress 2020

    Anti-parkinson effect of natural L-DOPA containing drug Mucuna pruriens against the rotenone induced rat model of Parkinson’s disease

    V. Kumar, F. Anwar (Allahabad, India)

    Objective: The nanoherbaceutical formulation comprising natural L-DOPA from Mucuna pruriens against rotenone caused Parkinson's disease in rats to be prepared and evaluated. Background: Parkinson's disease…
  • 2019 International Congress

    Smartphone-based gait assessment of psychiatric patients on neuroleptics

    S. Hassin-Baer, T. Fay-Karmon, V. Livneh, S. Israeli-Korn, Y. Rubel, K. Tchelet, Z. Yekutieli, M. Linder, H. Yahalom, G. Yahalom (Ramat-Gan, Israel)

    Objective: To characterize gait performance recorded from psychiatric patients on neuroleptics (PPN) and to compare it to Parkinson’s disease (PD) patients and healthy controls (HC).…
  • 2019 International Congress

    Waiting and waiting on Dopamine transporter imaging in drug induced parkinsonism

    JY. Yun, CY. Lee, MY. Chun, B. Jeon (Seoul, Republic of Korea)

    Objective: We discontinued offending medications in DIP or unmasked parkinsonism patients and delayed taking DAT images for one month. Background: Drug induced parkinsonism (DIP) may…
  • 2019 International Congress

    Formulations and evaluations of Intranasal Nose to Brain Delivery of Curcumin with resveratrol Nanoparticle for treatment of Parkisonism

    A. Jain, S. Jain (Sagar, India)

    Objective: Parkinson’s disease (PD) is a common neurodegenerative disease characterized by motor symptoms of tremor, rigidity, bradykinesia, and postural instability. Growing evidence indicates that resveratrol…
  • 2019 International Congress

    Design, characterization and In vivo evaluation of intranasal delivery of levodopa loaded microspere for Parkinsonism

    S. Jain, A. Jain, SB. Bhargav (Sagar, India)

    Objective: Levodopa is the drug of choice in the treatment of Parkinson's disease but it exhibits low oral bioavailability and very low brain uptake. The…
  • 2019 International Congress

    Development Of Anti-Parkinsonism Poly Herbal Sustained Release Formulation Composed Of Potential Traditional Plant Extracts

    S. Jain, A. Jain, S. Bhargav (Sagar, India)

    Objective: Parkinsonism is one of the commonest neurodegenerative diseases, which is characterized by a selective and progressive degeneration of dopaminergic neurons, causing a series of…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 10
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley